190 related articles for article (PubMed ID: 35101230)
1. Targeting RAS oncogenesis with SOS1 inhibitors.
Hillig RC; Bader B
Adv Cancer Res; 2022; 153():169-203. PubMed ID: 35101230
[TBL] [Abstract][Full Text] [Related]
2. Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature.
Thompson SK; Buckl A; Dossetter AG; Griffen E; Gill A
Expert Opin Ther Pat; 2021 Dec; 31(12):1189-1204. PubMed ID: 34253125
[No Abstract] [Full Text] [Related]
3. Targeting Son of Sevenless 1: The pacemaker of KRAS.
Kessler D; Gerlach D; Kraut N; McConnell DB
Curr Opin Chem Biol; 2021 Jun; 62():109-118. PubMed ID: 33848766
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B
Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722
[TBL] [Abstract][Full Text] [Related]
5. Development of Son of Sevenless Homologue 1 (SOS1) Modulators To Treat Cancers by Regulating RAS Signaling.
Luo G; Wang B; Hou Q; Wu X
J Med Chem; 2023 Apr; 66(7):4324-4341. PubMed ID: 36987571
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancers.
Chen T; Tang X; Wang Z; Feng F; Xu C; Zhao Q; Wu Y; Sun H; Chen Y
Eur J Med Chem; 2023 Dec; 261():115828. PubMed ID: 37778239
[TBL] [Abstract][Full Text] [Related]
7. Rational design of small molecule inhibitors targeting the Ras GEF, SOS1.
Evelyn CR; Duan X; Biesiada J; Seibel WL; Meller J; Zheng Y
Chem Biol; 2014 Dec; 21(12):1618-28. PubMed ID: 25455859
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Aminopiperidine Indoles That Activate the Guanine Nucleotide Exchange Factor SOS1 and Modulate RAS Signaling.
Abbott JR; Hodges TR; Daniels RN; Patel PA; Kennedy JP; Howes JE; Akan DT; Burns MC; Sai J; Sobolik T; Beesetty Y; Lee T; Rossanese OW; Phan J; Waterson AG; Fesik SW
J Med Chem; 2018 Jul; 61(14):6002-6017. PubMed ID: 29856609
[TBL] [Abstract][Full Text] [Related]
9. Small Molecule-Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1.
Howes JE; Akan DT; Burns MC; Rossanese OW; Waterson AG; Fesik SW
Mol Cancer Ther; 2018 May; 17(5):1051-1060. PubMed ID: 29440291
[TBL] [Abstract][Full Text] [Related]
10. Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices.
Leshchiner ES; Parkhitko A; Bird GH; Luccarelli J; Bellairs JA; Escudero S; Opoku-Nsiah K; Godes M; Perrimon N; Walensky LD
Proc Natl Acad Sci U S A; 2015 Feb; 112(6):1761-6. PubMed ID: 25624485
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Sulfonamide-Derived Agonists of SOS1-Mediated Nucleotide Exchange on RAS Using Fragment-Based Methods.
Sarkar D; Olejniczak ET; Phan J; Coker JA; Sai J; Arnold A; Beesetty Y; Waterson AG; Fesik SW
J Med Chem; 2020 Aug; 63(15):8325-8337. PubMed ID: 32673492
[TBL] [Abstract][Full Text] [Related]
12. High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling.
Burns MC; Howes JE; Sun Q; Little AJ; Camper DV; Abbott JR; Phan J; Lee T; Waterson AG; Rossanese OW; Fesik SW
Anal Biochem; 2018 May; 548():44-52. PubMed ID: 29444450
[TBL] [Abstract][Full Text] [Related]
13. Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS.
Hodges TR; Abbott JR; Little AJ; Sarkar D; Salovich JM; Howes JE; Akan DT; Sai J; Arnold AL; Browning C; Burns MC; Sobolik T; Sun Q; Beesetty Y; Coker JA; Scharn D; Stadtmueller H; Rossanese OW; Phan J; Waterson AG; McConnell DB; Fesik SW
J Med Chem; 2018 Oct; 61(19):8875-8894. PubMed ID: 30205005
[TBL] [Abstract][Full Text] [Related]
14. Identifying Potential SOS1 Inhibitors via Virtual Screening of Multiple Small Molecule Libraries against KRAS-SOS1 Interaction.
Ikram S; Sayyah E; Durdağı S
Chembiochem; 2024 Jun; 25(12):e202400008. PubMed ID: 38622060
[TBL] [Abstract][Full Text] [Related]
15. CIIA negatively regulates the Ras-Erk1/2 signaling pathway through inhibiting the Ras-specific GEF activity of SOS1.
Hwang HS; Hwang SG; Yoon KW; Yoon JH; Roh KH; Choi EJ
J Cell Sci; 2014 Apr; 127(Pt 8):1640-6. PubMed ID: 24522193
[TBL] [Abstract][Full Text] [Related]
16. Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras.
Hamilton G; Stickler S; Rath B
Curr Pharm Des; 2023; 29(22):1741-1746. PubMed ID: 37073657
[TBL] [Abstract][Full Text] [Related]
17. SOS GEFs in health and disease.
Baltanás FC; Zarich N; Rojas-Cabañeros JM; Santos E
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188445. PubMed ID: 33035641
[TBL] [Abstract][Full Text] [Related]
18. Frontline Science: TNF-α and GM-CSF1 priming augments the role of SOS1/2 in driving activation of Ras, PI3K-γ, and neutrophil proinflammatory responses.
Suire S; Baltanas FC; Segonds-Pichon A; Davidson K; Santos E; Hawkins PT; Stephens LR
J Leukoc Biol; 2019 Oct; 106(4):815-822. PubMed ID: 30720883
[TBL] [Abstract][Full Text] [Related]
19. Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS.
Sheffels E; Kortum RL
J Med Chem; 2021 May; 64(10):6566-6568. PubMed ID: 33961431
[TBL] [Abstract][Full Text] [Related]
20. Identification and Characterization of Oncogenic
Cai D; Choi PS; Gelbard M; Meyerson M
Mol Cancer Res; 2019 Apr; 17(4):1002-1012. PubMed ID: 30635434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
